Sign up to watch this video
Free access to all Sound Bites content
Dr. Wade Iams describes an MDT approach to optimally care for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 3/3)
Published 1 week
Medical Professional
MDT approach for patients on 1L ami subQ + laz
More in this series: COPERNICUS_2026
Related Videos
Dr. Wade Iams describes an MDT approach to optimally care for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 3/3)
Wade Iams, MD
Dr. Rahul Banerjee highlights key findings with iberdomide, daratumumab, and dexamethasone in RRMM. (Video 2/3)
Rahul Banerjee, MD
Dr. Gabriela Hobbs discusses event-free survival outcomes with ropeginterferon in polycythemia vera (Video 3/3)
Gabriela Hobbs, MD
Dr. Eytan Stein explores how emerging clinical data and real-world experience are shaping the treatment landscape in AML (Video 3/3)
Eytan Stein, MD
Dr. Wade Iams reviews the efficacy of dose interruption/reduction strategies for patients with EGFRm mNSCLC on 1L amivantamab + lazertinib (Video 2/3)
Wade Iams, MD
What sets iberdomide apart from established IMiDs? Dr. Rahul Banerjee explains. (Video 1/3)
Rahul Banerjee, MD
IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America
© 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.